NVG-291 is a first-in-class drug candidate currently in a Phase 1 clinical trial in healthy volunteers to evaluate safety, tolerability and metabolism. After completing our Phase 1 clinical trial, we plan to initiate Phase 1b/2 clinical trials in Alzheimer’s and spinal cord injury in 2022 and a Phase 2 in multiple sclerosis in 2023.
It is generally best to start your search for a clinical trial by speaking with your treating physician. Talk to them about any trials that might be right for your condition. As they may not be aware of all available trials, you can also search for trials online at www.clinicaltrials.gov, https://health-products.canada.ca/, www.anzctr.org.au, or https://eudract.ema.europa.eu/, which are searchable databases of clinical trials done in various parts of the world. Any clinical trials conducted by NervGen will be listed on one or more of these websites.
Currently, NVG-291 is being tested in a Phase 1 study in healthy volunteers. NervGen plans to initiate clinical trials in Alzheimer’s and spinal cord injury in 2022 and multiple sclerosis in 2023.
Not every clinical trial will be suitable. All clinical trials have guidelines, called eligibility criteria, that outline who can and cannot participate. These include things like age and specific characteristics of an individual’s underlying condition. You can talk about these criteria with your doctor or the study organizers to better understand how you may or may not qualify for a study.
If you find a clinical trial that seems of interest, contact the study organizers (phone and/or email address is listed on the website). They can put you in touch with the team of medical professionals running the trial. This team will then discuss next steps to see if you might be a good fit for the trial.
NervGen (TSX-V: NGEN, OTCQX: NGENF) is a clinical stage biotech company dedicated to developing innovative treatments that enable the nervous system to repair itself following damage, whether due to injury or disease. The company’s initial focus is on Alzheimer’s, spinal cord injury and multiple sclerosis.
Contact
2955 Virtual Way
Suite 480
Vancouver, BC V5M 4X6
Phone: (778) 731-1711
Email: info@nervgen.com